Skip to contentI
Inovio Pharmaceuticals, Inc.
I
INOInovio Pharmaceuticals, Inc. Q3 2019 · 10-Q
Revenue$866.86K$866.86K−56.7% vs Q3 2018 Net Income-$23.09M-$23.09MN/M vs Q3 2018 EPS Diluted-$0.25-$0.25N/M vs Q3 2018 Operating Income-$23,951,787N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inovio Pharmaceuticals, Inc. · CIK 1055726 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$27,867,134N/M Margins · derivedOperating margin-2763.0%−1431.5 pt vs Q3 2018
Net margin-2663.7%−1413.5 pt vs Q3 2018
ended Sep 30, 2019 · filed Nov 12, 2019 · 43 d after period end